ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,121 to 2,140 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
BCG-vaccine vs Control Children: Atopic Dermatitis466 of 2,052

495 of 1,952

-2.6 points

-5.3 to -0.0

4,004NCT01694108

Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.

Belimumab 10 mg/kg vs Placebo: Number of Deaths - On Treatment Period (Week 52)10 of 2,002

8 of 2,001

0.1 points

-0.3 to 0.6

4,003NCT01705977

Belimumab Assessment of Safety in SLE

Belimumab 10 mg/kg vs Placebo: Number of Participants With Serious Adverse Events (SAEs) Reported During On-treatment Period (Week 52)220 of 2,002

222 of 2,001

-0.1 points

-2.1 to 1.8

4,003NCT01705977

Belimumab Assessment of Safety in SLE

Belimumab 10 mg/kg vs Placebo: Number of Deaths Reported - On-study Period (Week 52)13 of 2,002

22 of 2,001

-0.5 points

-1.1 to 0.1

4,003NCT01705977

Belimumab Assessment of Safety in SLE

Belimumab 10 mg/kg vs Placebo: Number of Participants With SAEs Reported During On-study Period (Week 52)233 of 2,002

241 of 2,001

-0.4 points

-2.4 to 1.6

4,003NCT01705977

Belimumab Assessment of Safety in SLE

Belimumab 10 mg/kg vs Placebo: deaths from any cause51 of 2,002

80 of 2,001

-1.5 points

-2.6 to -0.3

4,003NCT01705977

Belimumab Assessment of Safety in SLE

Belimumab 10 mg/kg vs Placebo: serious adverse events233 of 2,002

241 of 2,001

-0.4 points

-2.4 to 1.6

4,003NCT01705977

Belimumab Assessment of Safety in SLE

Kidney Action Team Recommendations vs Usual Care: Percentage of Patients Who Receive Inpatient Dialysis31 of 1,999

30 of 2,004

0.1 points

-0.7 to 0.8

4,003NCT04040296

Personalized Recommendations for Acute Kidney Injury (AKI) Care

Kidney Action Team Recommendations vs Usual Care: Percent of Patients Who Receive a Kidney Consult Within 14 Days321 of 1,999

284 of 2,004

1.9 points

-0.3 to 4.1

4,003NCT04040296

Personalized Recommendations for Acute Kidney Injury (AKI) Care

Kidney Action Team Recommendations vs Usual Care: Percentage of Inpatient Mortality191 of 1,999

185 of 2,004

0.3 points

-1.5 to 2.1

4,003NCT04040296

Personalized Recommendations for Acute Kidney Injury (AKI) Care

Kidney Action Team Recommendations vs Usual Care: Percentage of Patients With Progression of Acute Kidney Injury270 of 1,999

261 of 2,004

0.5 points

-1.6 to 2.6

4,003NCT04040296

Personalized Recommendations for Acute Kidney Injury (AKI) Care

Kidney Action Team Recommendations vs Usual Care: Percent of Patients Who Are Discharged to Hospice Care 14 Days87 of 1,999

106 of 2,004

-0.9 points

-2.3 to 0.4

4,003NCT04040296

Personalized Recommendations for Acute Kidney Injury (AKI) Care

Kidney Action Team Recommendations vs Usual Care: Composite Outcome Showing the Percentage of Participants With Any One of the Following: Progression of AKI, Inpatient Dialysis, or Inpatient Death395 of 1,999

369 of 2,004

1.3 points

-1.1 to 3.8

4,003NCT04040296

Personalized Recommendations for Acute Kidney Injury (AKI) Care

Kidney Action Team Recommendations vs Usual Care: deaths from any cause191 of 1,999

185 of 2,004

0.3 points

-1.5 to 2.1

4,003NCT04040296

Personalized Recommendations for Acute Kidney Injury (AKI) Care

Trial Mailed FIT Intervention - Age Group 50-75 vs Trial Usual Care - Age Group 50-75: Proportion of Subjects Who Completed Colorectal Cancer (CRC) Screening Within 6 Months (Trial - Age Group 50-75)598 of 2,001

192 of 2,001

20.3 points

17.9 to 22.7

4,002NCT04406714

Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)

FSC Cohort vs AC Cohort: Number of Participants With Any Chronic Obstructive Pulmonary Disease (COPD)-Related Exacerbation200 of 1,078

674 of 2,923

-4.5 points

-7.2 to -1.7

4,001NCT01337336

Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population

CYD Dengue Vaccine Group vs Control Group: deaths from any cause1 of 2,666

4 of 1,331

-0.3 points

-0.7 to -0.0

3,997NCT00842530

Efficacy and Safety of Dengue Vaccine in Healthy Children

CYD Dengue Vaccine Group vs Control Group: serious adverse events315 of 2,666

176 of 1,331

-1.4 points

-3.7 to 0.7

3,997NCT00842530

Efficacy and Safety of Dengue Vaccine in Healthy Children

No Mobile Phone-administered Triage Tool vs Mobile Phone-administered Triage Tool: Proportion of Successful Contacts837 of 1,491

1,514 of 2,499

-4.4 points

-7.6 to -1.3

3,990NCT03805646

Mobile Phone-administered Triage Tool to Followup on Discharged Trauma Patients

No Mobile Phone-administered Triage Tool vs Mobile Phone-administered Triage Tool: deaths from any cause40 of 1,491

49 of 2,499

0.7 points

-0.2 to 1.8

3,990NCT03805646

Mobile Phone-administered Triage Tool to Followup on Discharged Trauma Patients

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=107"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=107

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01694108-0f074784",
        "title": "BCG-vaccine vs Control Children: Atopic Dermatitis",
        "summary": "466 of 2052 against 495 of 1952; risk difference -2.6 points, 95% interval -5.3 to -0.0; NCT01694108, Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.",
        "record": "/library/comparisons/NCT01694108-0f074784",
        "nct_id": "NCT01694108",
        "kind": "outcome",
        "participants": 4004,
        "risk_difference": {
          "value": -0.026490549004569736,
          "lower": -0.052965441717791314,
          "upper": -0.000022907952555648037
        },
        "group_1": "466 of 2,052",
        "group_2": "495 of 1,952",
        "difference": "-2.6 points",
        "interval": "-5.3 to -0.0",
        "trial_title": "Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children."
      },
      {
        "id": "NCT01705977-0baa05e4",
        "title": "Belimumab 10 mg/kg vs Placebo: Number of Deaths - On Treatment Period (Week 52)",
        "summary": "10 of 2002 against 8 of 2001; risk difference 0.1 points, 95% interval -0.3 to 0.6; NCT01705977, Belimumab Assessment of Safety in SLE",
        "record": "/library/comparisons/NCT01705977-0baa05e4",
        "nct_id": "NCT01705977",
        "kind": "outcome",
        "participants": 4003,
        "risk_difference": {
          "value": 0.0009970039955047453,
          "lower": -0.0034957816189339222,
          "upper": 0.005614266000875675
        },
        "group_1": "10 of 2,002",
        "group_2": "8 of 2,001",
        "difference": "0.1 points",
        "interval": "-0.3 to 0.6",
        "trial_title": "Belimumab Assessment of Safety in SLE"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=108",
  "request_id": "unXPOdjgeiek4qPg"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?